|
WO2020017571A1
|
|
Flurbiprofen-axetil-containing fat emulsion and method for manufacturing same
|
|
CN111447927A
|
|
Naloxone transdermal drug delivery device and method of use thereof
|
|
KR20190060007A
|
|
How to manage pain using Dexmedetomidine transdermal device
|
|
CN106413695A
|
|
Rivastigmine transdermal compositions and methods of using same
|
|
US2015098981A1
|
|
Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
|
|
CN106456561A
|
|
Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
|
|
KR20160065200A
|
|
Dexmedetomidine transdermal delivery devices and methods for using the same
|
|
KR20180021902A
|
|
Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
|
|
KR20180095733A
|
|
Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
|
|
EP3054933A1
|
|
Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
|
|
WO2015053879A1
|
|
Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
|
|
CN104936582A
|
|
Compositions and methods for transdermal delivery of hormones and other medicinal agents
|
|
US2014186421A1
|
|
Extended buprenorphine transdermal delivery compositions and methods for using the same
|
|
CA2887705A1
|
|
Propynylaminoindan transdermal compositions
|
|
JO3685B1
|
|
Non-aqueous taxane nanodispersion formulations and methods of using the same
|
|
US2013261188A1
|
|
Ibuprofen Solid Oral Dosage Composition Comprising a Methacrylic Acid Copolymer
|
|
CA2846957A1
|
|
General medication disposal system
|
|
CA2846956A1
|
|
Transdermal patch disposal system
|
|
KR20140016293A
|
|
Transdermal compositions comprising an active agent layer and an active agent conversion layer
|
|
CN102970990A
|
|
Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
|
